Proposed ABs were based on behavioural not clinical PD-0332991 price manifestations. Descriptive statistics and simple (non-weighted) risk scores were constructed on aggregate counts (score ≥ 3 considered ‘high-risk’). Univariate analysis explored characteristics of patients with

ABs; Crude odds ratios (OR) + 95% CI were calculated. In 551 patients, frequently reported pre-existing risk factors for dependence were smoking (n = 119, 21.6%) and psychiatric disorders (n = 42, 7.6%). One or more risk factors were reported in 145 patients (26.3%); 6 patients were considered high risk. One or more ABs were reported in 46 patients (8.3%); 9 patients were considered high-risk. Compared to those without, patients with ABs were: younger (median age (yrs) INCB024360 solubility dmso 48 vs 63; p < 0.001); received higher test, effective and/or maintenance doses (p ≤ 0.019); had longer treatment duration (median (days) 87 vs 21; p < 0.001); and were more likely to have: indications other than break through pain in cancer [OR 3.5 (1.1, 10.8)], a history of alcohol/substance misuse and psychiatric disorders.Where specified (n = 20) in 11 patients, ABs were pre-existing. The prevalence of at least one pre-existing risk factor for dependence was 26% whilst the frequency of ABs observed during treatment

was 8%. Patients with ABs had several different characteristics to patients without. This study

demonstrates the feasibility of systematic collection of HCP reports of ABs and the development of risk scores using these reports to support the post-marketing risk management of products with misuse potential. Study limitations include subjectivity to in relation to HCPs identifying ABs, and under-reporting. The presence of these criteria do not confirm misuse, but should be considered as signals of problematic opioid misuse, which require further investigation. 1. Katz NP, Adams EH, Benneyan JC, Birnbaum HG, Budman SH, Buzzeo RW et al. Foundations of opioid risk management. Clin J Pain 2007; 23: 103–118. 2. European Commission. Volume 9A – Pharmacovigilance for Medicinal Products for Human Use. March 2007 Available at URL: http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/homev9.htm. Date accessed 04/10/2007 Joanne Kember, Karen Hodson, Delyth Higman James Cardiff University, Cardiff, UK Exploration of the public perception of the role of the Community Pharmacist, based on five focus groups representing users and non-users of pharmacy services. Although the traditional dispensing and supply of medicines roles were clearly recognised, in general a poor awareness of the newer services emerged, particularly with regards to public health roles.